What is HC Wainwright’s Forecast for VNDA FY2024 Earnings?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Investment analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a report issued on Thursday, October 31st. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will earn ($0.48) per share for the year. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.49) per share.

A number of other research analysts also recently commented on the company. StockNews.com began coverage on Vanda Pharmaceuticals in a research note on Friday. They issued a “hold” rating on the stock. Cantor Fitzgerald boosted their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $4.65 on Friday. The firm has a fifty day moving average of $4.84 and a two-hundred day moving average of $5.23. Vanda Pharmaceuticals has a 12-month low of $3.30 and a 12-month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The company had revenue of $50.47 million during the quarter.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Sei Investments Co. lifted its position in shares of Vanda Pharmaceuticals by 39.6% in the first quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock worth $2,132,000 after buying an additional 147,066 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Vanda Pharmaceuticals in the 1st quarter valued at approximately $1,158,000. Acadian Asset Management LLC raised its stake in shares of Vanda Pharmaceuticals by 4.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock valued at $9,740,000 after acquiring an additional 107,203 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in Vanda Pharmaceuticals in the 2nd quarter worth approximately $1,090,000. Finally, Empowered Funds LLC boosted its position in Vanda Pharmaceuticals by 8.2% during the first quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company’s stock worth $827,000 after purchasing an additional 15,215 shares during the period. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.